Article Text

PDF

070 Enzyme replacement therapy improves cardiac features of Fabry disease
  1. M Motwani,
  2. S Banypersad,
  3. P Woolfson,
  4. S Waldek
  1. Salford Royal Hospital NHS Foundation Trust, UK

Abstract

Introduction Fabry disease (FD) is an X linked deficiency of α-galactosidase A which leads to an accumulation of globotriaosylceramide (GL-3) throughout the body, particularly in the heart, brain and kidneys. Although left ventricular hypertrophy (LVH) in FD can improve with enzyme-replacement therapy (ERT), the response is difficult to predict. Furthermore, the response of other cardiac features such as aortic dilatation and ECG changes are poorly understood.

Methods A local registry of 66 patients with FD was studied. ECG, echocardiogram and Fabry Outcome Survey-Mainz Severity Score Index (FOS-MSSI) data were compared between baseline and after long-term ERT (median 36 months).

Results In patients with LVH (n=42), left ventricular mass index (LVMI), maximal wall thickness (MWT), left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF) were all seen to improve after ERT (LVMI: 135±13 vs 133±13 g/m2, MWT: 17±6 vs 16±5 mm, LVEDD: 55±6 vs 54±6 mm; EF: 62±5 vs 64±3%; p<0.05) (Abstract 070 figure 1). In the entire patient group, PQ interval and P wave duration significantly increased with ERT (PQ: 131±13 vs 144±13 ms, P: 76±5 vs 90±6 ms; p values <0.001); QTc interval significantly decreased (418±18 vs 410±15 ms; p<0.001); and median FOS-MSSI score fell from 16 to 14 (p<0.001) (Abstract 070 figure 2). On logistic-regression analysis, none of the recorded baseline features (age, gender, LVMI, MWT, LVEDD, aortic diameter, EF, PQ interval, P wave duration, QRS duration, QT interval, Romhilt-Estes score or FOS-MSSI) predicted improvements in LVH or FOS-MSSI with ERT (p>0.05).

Abstract 070 Figure 1

Effect of enzyme replacement therapy (ERT) on LV morphology and function in patients with LVH at baseline. Left ventricular mass index (LVMI), maximal wall thickness (MWT), LV end-diastolic diameter (LVEDD) and ejection fraction all showed significant improvements (all p values <0.05) at the end of follow-up (median 3 years). [Values shown are mean±SD].

Abstract 070 Figure 2

Effect of enzyme replacement (ERT) on the conduction system. There was a significant increase in P wave duration and PQ interval from baseline; there was a significant decrease in QRS width and QTc interval from baseline at the end of follow-up (median 3 years). [Values shown are mean±SD].

Conclusions ERT improved LV morphology and function in patients with LVH- but there was no relationship between age, gender, FOS-MSSI or baseline ECG/TTE features and the response. ERT also normalised long QTc intervals, short PQ intervals and short P waves; and reduced disease burden (FOS-MSSI).

  • Fabry disease
  • LVH
  • enzyme replacement therapy

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.